Bayer has decided to take Cipla to the Supreme the grant of marketing approval under the Drugs and Cosmetics Act (DCA) to Cipla’s drug Sorafenib. A Bench headed by Justice Dalveer Bhandari has posted the matter for hearing today.
You will recall Prakruthi’s comprehensive post on the decision of the Division Bench of the Delhi High Court in the matter a fortnight or so ago. The Division Bench had essentially upheld the decision of a Single Judge in the matter, which had ruled in Cipla’s favour.
We will keep you posted on developments as and when we hear of them. Meanwhile, I remain surprised that Bayer should persist in their arguments, despite what seems to me to have been a very sound decision the Delhi High Court. For those of you who still haven’t had a chance to read the DB judgement, it’s available on the High Court website as a download here. More on this in the days to come.